In humans, immunotherapy using monoclonal antibodies targeting the PD-1/PD-L1/PD-L2 axis has revolutionized the treatment of malignant neoplasms, including metastatic triple-negative breast cancer, with astonishing results. Here, PDCD1 is linked to triple-negative breast carcinoma.